Skip to main content
MedGenome logo

MedGenome

Updated Mar 24, 2026

A deep look at MedGenome's finances, team, and market position in the AI Healthcare space.

🇮🇳IndiaSeries EAI Healthcare

Out of 100

🇮🇳

HQ

India

🗓

Founded

2013

💰

Raised

$264M

🏷️

Stage

Series E

👥

Team

200-500

MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population

Is this your company? Claim it →

Key Facts

  • MedGenome has raised a total of $264M in disclosed funding across 6 funding rounds.
  • MedGenome was founded in 2013 by Sam Santhosh and is headquartered in India.
  • MedGenome employs approximately 200-500 people.
  • MedGenome operates in the AI Healthcare category and is currently at the Series E stage.
  • MedGenome has an Awaira Score of 63/100, ranking it among the tracked AI companies on Awaira.
  • MedGenome's most recent funding round was a Series E of $84.48M closed in February 2020.

Source: Awaira · Updated Mar 24, 2026

N/A

Post-money

$264M

All rounds

63/100

2013

200-500 employees

Strengths

Strong Awaira Score of 63/100

Large team of 200-500+ employees

Established market presence (founded 2013)

Considerations

!

Valuation not publicly disclosed

Analysis based on publicly available data. Not investment advice.

6

Total Rounds

$44M

Avg Round Size

6.8yr

Funding Span

MedGenome raised 6 rounds over 6.8 years, averaging $44M per round — a pace of roughly one round every 14 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$20M–$100M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does MedGenome stack up against competitors?

MetricMedGenomeButterfly NetworkTempusAlan
Awaira Score63/10085/10084/10083/100
Total Raised$264M$370M$1.05B$750M
ValuationN/A$957M$8.1B$5.83B
StageSeries EPublicPublicSeries D
Founded2013201120152016
Employees200-500500-10002500500-1000
Country🇮🇳🇺🇸🇺🇸🇫🇷
S

Sam Santhosh

Founder & CEO

View founder profile →
StageSeries E
Employees200-500
Country🇮🇳 India
Connect
Inactive
6 rounds
Series ELatest

$84.48M

Feb 2020

Series D

$73.92M

Oct 2018

Series C

$55.44M

Jun 2017

Series B

$31.68M

Feb 2016

Series A

$13.2M

Oct 2014

Seed

$5.28M

Jun 2013

Frequently Asked Questions

What is MedGenome's valuation?
There's no publicly available valuation data at this time. As a Series E company in AI Healthcare, the market value remains undetermined.
Who invested in MedGenome?
Investor details haven't been made public yet. Check back for updates as new funding rounds are announced.
When did MedGenome last raise funding?
Last raise: a Series E of $84.48M in February 2020.
How many employees does MedGenome have?
The team is roughly 200-500 people, headquartered in India.
What does MedGenome do?
MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.
Who founded MedGenome?
Sam Santhosh founded the company in 2013 in India. Sam Santhosh serves as Founder & CEO.
Is MedGenome profitable?
There's no public reporting on profitability. With raised $264M in total funding, the company remains at the Series E stage.
Where is MedGenome headquartered?
Based in India 🇮🇳, the company runs its operations in the AI Healthcare space and was established in 2013.
⚔️

Compare MedGenome

See how MedGenome stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →